Table 2.
Characteristics of the patients with Covid-19 associated ARDS and lipase serum activity >180 U/l versus <180 U/L (BMI: body mass index).
| Patients with Covid-19 associated ARDS and lipase activity | >180 U/l | <180 U/l | P | |
|---|---|---|---|---|
| Age (range) | 70.5 (51–84) | 60.5 (26–84) | 0.710 | |
| Gender m:f | 6:1 | 4.3:1 | 0.709 | |
| BMI | 26.9 ± 6.0 | 24.9 ± 7.7 | 0.809 | |
| Days till viral clearance | 22.5 ± 7.3 | 17.3 ± 10.4 | 0.149 | |
| Follow up in days | 35.8 ± 8.3 | 29.8 ± 15.3 | 0.135 | |
| at last follow up consultation | Necrotic collection or walled of necrosis | 0/12 (0%) | ||
| serum glucose level > 200 mg/dl | 0/12 (0%) | |||
| Symptoms | ||||
| Fever | 7/12 (58.3%) | 19/26 (73.1%) | 0.363 | |
| Malaise | 7/12 (58.3%) | 21/26 (80.8%) | 0.144 | |
| Dyspnea | 5/12 (41.7%) | 15/26 (57.7%) | 0.358 | |
| Cough | 3/12 (25%) | 15/26 (57.7%) | 0.060 | |
| Acute renal failure | 3/12 (25%) | 5/26 (19.2%) | 0.685 | |
| Diarrhea | 1/12 (8.3%) | 5/26 (19.2%) | 0.392 | |
| Somnolence | 1/12 (8.3%) | 0/26 | 0.316 | |
| Comorbidities | ||||
| Hypertension | 5/12 (41.7%) | 21/26 (80.8%) | 0.016 | |
| COPD or lung fibrosis | 3/12 (25%) | 5/26 (19.2%) | 0.685 | |
| Chronic kidney disease | 2/12 (16.7%) | 7/26 (26.9%) | 0.489 | |
| Diabetes | 1/12 (8.3%) | 11/26 (42.3%) | 0.036 | |
| No comorbidities | 3/12 (25%) | 3/26 (11.5%) | 0.290 | |
| Others include: | leukemia, lymphoma, chronic heart failure, hepatic steatosis, pericardial effusion, alcohol abuse | |||
| Organ failure | ||||
| Respiratory failure | 12/12 (100%) | 26/26 (100%) | ||
| Days on mechanical ventilation | 19.3 ± 11.7 | 14.7 ± 12.1 | 0.053 | |
| Renal failure | 7/12 (58.3%) | 11/26 (42.3%) | 0.358 | |
| Liver failure | 2/12 (16.7%) | 3/26 (11.5%) | 0.664 | |